Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/13769
Title: Engineered liposomes in interventional theranostics of solid tumors
Authors: Kommineni, Nagavendra
Chaudhari, Ruchita
Conde, Joao
Tamburacı, Sedef
Cecen, Berivan
Chandra, Pranjal
Prasad, Rajendra
Keywords: Liposomes
Interventional theranostic
Solid tumors
Nanoimaging
Publisher: American Chemical Society
Abstract: Engineered liposomal nanoparticles have unique characteristicsas cargo carriers in cancer care and therapeutics. Liposomal theranosticshave shown significant progress in preclinical and clinical cancermodels in the past few years. Liposomal hybrid systems have not onlybeen approved by the FDA but have also reached the market level. Nanosizedliposomes are clinically proven systems for delivering multiple therapeuticas well as imaging agents to the target sites in (i) cancer theranosticsof solid tumors, (ii) image-guided therapeutics, and (iii) combinationtherapeutic applications. The choice of diagnostics and therapeuticscan intervene in the theranostics property of the engineered system.However, integrating imaging and therapeutics probes within lipidself-assembly liposome may compromise their overalltheranostics performance. On the other hand, liposomal systems sufferfrom their fragile nature, site-selective tumor targeting, specificbiodistribution and premature leakage of loaded cargo molecules beforereaching the target site. Various engineering approaches, viz., grafting,conjugation, encapsulations, etc., have been investigated to overcomethe aforementioned issues. It has been studied that surface-engineeredliposomes demonstrate better tumor selectivity and improved therapeuticactivity and retention in cells/or solid tumors. It should be notedthat several other parameters like reproducibility, stability, smoothcirculation, toxicity of vital organs, patient compliance, etc. mustbe addressed before using liposomal theranostics agents in solid tumorsor clinical models. Herein, we have reviewed the importance and challengesof liposomal medicines in targeted cancer theranostics with theirpreclinical and clinical progress and a translational overview.
URI: https://doi.org/10.1021/acsbiomaterials.3c00510
https://hdl.handle.net/11147/13769
ISSN: 2373-9878
Appears in Collections:Chemical Engineering / Kimya Mühendisliği
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
Engineered-Liposomes.pdf3.57 MBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

10
checked on Jun 14, 2024

WEB OF SCIENCETM
Citations

9
checked on Jun 15, 2024

Page view(s)

62
checked on Jun 10, 2024

Download(s)

30
checked on Jun 10, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.